Speciality Medicines IPO GMP Today, Price & Details
Speciality Medicines IPO GMP Today, Price Band, Subscription Status, Allotment & Listing Details
About Speciality Medicines
Speciality Medicines is a company operating within the pharmaceutical sector, focusing on the manufacturing and distribution of pharmaceutical formulations. The company's scale of operations can be gauged from its recent revenue figures. For the reported period, Speciality Medicines registered revenues of ₹36.72 crore and a Profit After Tax (PAT) of ₹6.06 crore, indicating a healthy profitability.
The company's operations are characterized by strong return ratios, with Return on Net Worth (RONW) at 28.3% and Return on Capital Employed (ROCE) at 33.39%, suggesting efficient utilization of capital. This IPO is structured as a 100% fresh issue, meaning the entire proceeds of ₹29.14 crore will be infused into the company for its business expansion and general corporate purposes. This fresh capital infusion is crucial for its growth trajectory, allowing it to potentially scale up manufacturing, enhance its product portfolio, or strengthen its distribution network.
In terms of competitive positioning, the company's focus on speciality medicines, coupled with its profitability metrics, suggests a niche market presence and effective operational management. The IPO offers an opportunity for investors to participate in the growth of a profitable pharmaceutical entity that is seeking to expand its operational capacity through this capital raise.
Speciality Medicines IPO — Investment Analysis
Speciality Medicines' IPO presents a valuation that warrants careful consideration. The company's Price-to-Earnings (P/E) ratio stands at 8.31x, based on its Earnings Per Share (EPS) of ₹14.1. This P/E appears to be on the lower side when compared to the typical valuation multiples seen in the broader pharmaceutical industry, which can often trade at higher P/E ratios.
This could suggest that the stock is potentially undervalued, or it might reflect the specific segment the company operates in or its growth prospects as an SME. The price-to-book value can be estimated by dividing the issue price of ₹117 by the Net Asset Value (NAV) of ₹47.26, which is approximately 2.47x, indicating a moderate premium to its book value. Financially, Speciality Medicines demonstrates a robust health profile.
Its revenue of ₹36.72 crore and PAT of ₹6.06 crore translate to a healthy PAT margin of approximately 16.5%. Furthermore, the EBITDA margin of 15.6% indicates efficient operational management before considering interest, taxes, depreciation, and amortization. The return ratios are particularly strong, with RONW at 28.3% and ROCE at 33.39%.
These high figures suggest that the company is effectively generating profits from its shareholder equity and its overall capital employed, pointing towards a quality business. In terms of growth outlook, the company's profitability and strong return ratios suggest a solid foundation. The fact that the entire IPO proceeds are a fresh issue, earmarked for growth capital, signals management's intent to expand the business.
However, as an SME IPO, the track record may be shorter compared to larger listed entities, and detailed historical financial trends might be less extensive. Key risks for investors include the inherent volatility associated with SME IPOs, which often experience higher price swings. The competitive landscape within the pharmaceutical sector is also intense, and factors such as regulatory changes, pricing pressures, and the success of new product launches can impact performance.
While the valuation appears attractive, the company's future growth trajectory will be contingent on its ability to effectively deploy the IPO proceeds and navigate market challenges. The subscription data shows an overwhelming total subscription of 49x, with zero subscriptions reported across Retail, NII, and QIB categories. This unusual subscription pattern, especially the zero reported interest from institutional and high-net-worth investors, alongside a significant overall subscription, warrants a deeper investigation into the reporting or the dynamics of the subscription process.
Investors should consult a SEBI-registered financial advisor before making investment decisions.
Disclaimer: This analysis is auto-generated from publicly available financial data and should not be considered investment advice. Always consult a SEBI-registered financial advisor before making investment decisions.
Speciality Medicines IPO — Pros & Cons
Strengths
- The company exhibits strong profitability metrics, with a PAT of ₹6.06 crore on revenues of ₹36.72 crore, indicating efficient cost management and pricing power.
- Exceptional return ratios, with RONW at 28.3% and ROCE at 33.39%, demonstrate the company's ability to generate substantial returns on shareholder investments and capital employed.
- The IPO is structured as a 100% fresh issue, providing direct capital for business expansion and growth initiatives, which is beneficial for long-term value creation.
- A P/E ratio of 8.31x appears attractive relative to potential industry averages, suggesting the IPO might be priced at a reasonable valuation.
- The company operates in the pharmaceutical sector, which generally has stable demand and potential for growth, especially in specialized segments.
Risks
- The subscription data shows zero reported interest from Retail, NII, and QIB categories despite a total subscription of 49x, which is an unusual and potentially concerning pattern that requires further scrutiny.
- As an SME IPO, Speciality Medicines may have a shorter financial track record and potentially less liquidity compared to mainboard companies, leading to higher stock volatility.
- The pharmaceutical industry is subject to stringent regulatory oversight and potential price controls, which could impact future profitability and growth.
- While the P/E ratio appears low, the actual future earnings growth needs to be robust to justify the current valuation and provide returns to investors.
- The company's reliance on specific speciality medicines could make it vulnerable to shifts in market demand or the emergence of alternative treatments.
Speciality Medicines IPO Details
| Company Name | Speciality Medicines |
|---|---|
| IPO Type | SME |
| Exchange | BSE |
| Price Band | ₹117 - ₹117 |
| Face Value | ₹10 per share |
| Lot Size | 1000 shares |
| Min Investment | ₹117,000 |
| Total Issue Size | ₹29.14 Cr |
|---|---|
| Fresh Issue | ₹29.14 Cr |
| IPO Status | Listed |
Speciality Medicines IPO Dates
Speciality Medicines IPO Subscription Status
Day-wise Subscription Trend
| Date | Retail | NII/HNI | QIB | Total |
|---|---|---|---|---|
| 30 Mar 2026 | 0.00x | 0.00x | 0.00x | 49.00x |
| 29 Mar 2026 | 0.00x | 0.00x | 0.00x | 49.00x |
| 28 Mar 2026 | 0.00x | 0.00x | 0.00x | 49.00x |
| 27 Mar 2026 | 0.00x | 0.00x | 0.00x | 49.00x |
| 24 Mar 2026 | 0.85x | 2.01x | 96.24x | 2.34x |
| 23 Mar 2026 | 0.19x | 1.82x | 1.00x | 1.01x |
| 20 Mar 2026 | 0.07x | 1.60x | 1.00x | 0.84x |
Speciality Medicines IPO Listing Performance
Speciality Medicines IPO listed on BSE on 30 Mar 2026 at ₹124, a premium of 6% over the issue price of ₹117. Investors who received allotment made a profit of ₹7,000 per lot (1000 shares) on listing day.
Speciality Medicines IPO — Key Highlights
- The Speciality Medicines IPO is a 100% fresh issue, aiming to raise ₹29.14 Cr for business expansion.
- The company reported revenue of ₹36.72 Cr and a Profit After Tax (PAT) of ₹6.06 Cr, indicating strong profitability.
- Return on Net Worth (RONW) stands at a robust 28.3%, and Return on Capital Employed (ROCE) is an impressive 33.39%.
- The IPO is priced at ₹117 per share, with a Price-to-Earnings (P/E) ratio of 8.31x.
- The total subscription for the IPO reached 49x, though with zero reported subscriptions in Retail, NII, and QIB categories.
- The Net Asset Value (NAV) per share is ₹47.26, suggesting the IPO price is approximately 2.47 times its book value.
Speciality Medicines Financial Performance
| Metric (₹ Cr) | FY 2023 | FY 2024* | FY 2025* | 7M FY 2026* |
|---|---|---|---|---|
| Revenue | 23.18 | 27.52 | 58.27 | 36.72 |
| Expenses | 20.24 | 23.10 | 49.85 | 30.80 |
| Net Income (PAT) | 1.70 | 2.93 | 8.61 | 6.06 |
Speciality Medicines IPO Valuations & Key Metrics
Valuation Ratios
| EPS | ₹14.10 |
|---|---|
| P/E Ratio | 8.31x |
| NAV | ₹47.26 |
| Debt/Equity | 0.170 |
Return Metrics
| RONW (%) | 28.30% |
|---|---|
| ROCE (%) | 33.39% |
| EBITDA Margin | 15.60% |
Speciality Medicines IPO Reservation / Allocation
Speciality Medicines IPO — Frequently Asked Questions
What is Speciality Medicines IPO GMP today?
As of today, the Grey Market Premium (GMP) for Speciality Medicines IPO is not available at this time. GMP values are updated daily based on grey market activity.
What is the price band and lot size of Speciality Medicines IPO?
Speciality Medicines IPO has a price band of ₹117 to ₹117 per equity share with a face value of ₹10. The minimum lot size is 1000 shares, requiring a minimum investment of ₹117,000 at the upper band.
What are the important dates for Speciality Medicines IPO?
Speciality Medicines IPO opens for subscription on 20 Mar 2026 and closes on 24 Mar 2026. Allotment is expected on 25 Mar 2026. The shares are expected to list on BSE on 30 Mar 2026.
What is the investor category allocation in Speciality Medicines IPO?
The shares are reserved as follows — Qualified Institutional Buyers (QIB): 36.72%, Non-Institutional Investors (NII/HNI): 0.00%, and Retail Individual Investors: 49.00%. Additionally, 6.06% is reserved for eligible employees.
How can I apply for Speciality Medicines IPO?
You can apply for Speciality Medicines IPO through your bank's net banking ASBA facility or via UPI-based application through any stockbroker platform. Ensure you have sufficient funds in your bank account as the amount will be blocked until allotment.
What is the subscription status of Speciality Medicines IPO?
Speciality Medicines IPO has been subscribed 2.34 times overall. Retail category: 0.85x, NII/HNI: 2.01x, QIB: 96.24x.
What is Speciality Medicines IPO price band and lot size?
The Speciality Medicines IPO has a fixed price band of ₹117 per share, meaning the issue price is set at ₹117. The lot size for this IPO is 1000 shares, which determines the minimum investment amount. Consequently, the minimum investment required to apply for one lot is ₹117,000 (1000 shares x ₹117 per share). The face value of each share is ₹10. Retail investors can apply for up to ₹2 lakh worth of shares, which translates to a maximum of one lot.
Is Speciality Medicines IPO worth investing in?
Speciality Medicines presents a mixed investment profile. The company boasts strong financial indicators, including healthy profit margins and impressive return ratios (RONW 28.3%, ROCE 33.39%), and a seemingly attractive P/E of 8.31x. The fact that it's a 100% fresh issue for growth capital is a positive sign for expansion. However, the unusual subscription data (zero retail, NII, QIB interest despite high total subscription) is a significant point of caution. SME IPOs also carry higher risks and volatility. Investors should carefully weigh these strengths against the potential risks and the unusual subscription dynamics. Investors should consult a SEBI-registered financial advisor before making investment decisions.
What is Speciality Medicines IPO GMP today?
Grey Market Premium (GMP) for an IPO reflects the unofficial demand and trading sentiment in the grey market before the shares are listed. As of now, specific GMP data for the Speciality Medicines IPO is not publicly available or widely reported. If any GMP is observed, it would be an unofficial indicator of market sentiment, potentially influenced by subscription levels and overall market conditions. However, GMP is speculative and should not be the sole basis for making investment decisions.
How to apply for Speciality Medicines IPO?
You can apply for the Speciality Medicines IPO through your stockbroker's trading platform using the UPI (Unified Payments Interface) mechanism. Alternatively, you can apply through your bank's net banking portal using the ASBA (Application Supported by Blocked Amount) facility. Once you submit your application, the funds will be blocked in your bank account and will only be debited upon successful allotment of shares. The registrar for this IPO is () if known. The application process is generally straightforward and can be completed online.